In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

BofA lowered the firm’s price target on BioNTech (BNTX) to $147 from $150 and keeps a Buy rating on the shares. On the Q4 call, the firm will ...

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T ...

Check the time stamp on this data. Updated AI-Generated Signals for Biontech Se (BNTX) available here: BNTX. Type a few ...

BioNTech's decline on Monday may reflect broader ... According to data from Benzinga Pro, BNTX has a 52-week high of $131.49 and a 52-week low of $76.53.

BNTX stock opened at $122.85 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The firm has a market capitalization of $29.45 billion, a ...

BioNTech (NASDAQ:BNTX – Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the ...

BioNTech's strong balance sheet and innovative mRNA technology show long-term promise, but regulatory and competitive challenges warrant patience before investing. The NAV model indicates BNTX is ...

Investors in BioNTech SE (Symbol: BNTX) saw new options begin trading this week, for the September 19th expiration. One of the key data points that goes into the price an option buyer is willing ...

Investors, analysts and the interested public are invited to join the event MAINZ, Germany, October 21, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...